Loading stock data…
DWTX
$1.46+0.03 (+2.10%)
Market ClosedLast close May 1
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dogwood Therapeutics, Inc. in the Healthcare sector is trading at $1.46. The stock is currently near its 52-week low of $1.28, remaining 66.0% below its 200-day moving average. Technical signals show oversold RSI of 26 and bullish MACD crossover, explaining why DWTX maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.46
Potential Upside
5%
Whystock Fair Value$1.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$14.00+858.9%
Range$12.00 – $15.00
Fundamentals
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$51.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.65%
Volume
Today's trading volume
48,919
Recent News
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Dogwood Therapeutics, Inc. is one of the oversold biotech stocks on this list. TheFly reported on April 15 that DWTX announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for SP16, an intravenous candidate being […]
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron
Dogwood Therapeutics (DWTX) said Monday that an interim analysis of its Phase 2b study for Halneuron
Potential Government Shutdown in Focus as US Equity Futures Rise Pre-Bell
US equity futures were higher pre-bell Monday as traders appeared to brush off concerns over a poten